A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.
Also called NCT01628107
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 406 participants
- Sponsor
- Registry
-
NCT01628107
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01628107. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07-16 (actual); primary completion 2015-01-02 (actual). Results posted on 2018-07-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
- Acronym
- AiME - 03
- Condition
- Chronic Renal Failure Requiring Hemodialysis
- Intervention (Biological)
- Epoetin Hospira
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01628107- Content hash
fdd70c554a094da6be82c5712ba682a1277e97f02269d080c6f480cbf6773d24